Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that its abstract, titled "Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites", has been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting April 25-30, 2025 in Chicago, IL.
This significant milestone reflects Calidi’s ongoing commitment to advancing systemic enveloped virotherapy as a transformative approach to target and kill metastatic cancers, which are the leading cause of cancer-related mortality. The data presented will focus on the development of Calidi's proprietary RTNova systemic platform, showcasing its potential to overcome current barriers in metastatic cancer treatment by enabling targeted systemic delivery to multiple tumor sites without rapid elimination by the body’s immune system.
This systemic platform addresses the challenges of treating advanced-stage metastatic cancers, including lung cancer, when intratumoral administration is not feasible. Calidi designed a novel vaccinia virus strain that is enveloped with a human cell membrane (extracellular enveloped virus or EEV) that offers protection while targeting distant tumors and upon reaching the tumor, induces a robust response from the patient’s immune cells which produces a more durable therapeutic effect.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.